{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T20:28:21Z","timestamp":1781468901701,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40120-022-00410-3","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T19:03:02Z","timestamp":1666292582000},"page":"73-87","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02959177","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hisaka","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5510-4219","authenticated-orcid":false,"given":"Akichika","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taka","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"issue":"2","key":"410_CR1","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","volume":"163","author":"S Safiri","year":"2022","unstructured":"Safiri S, Pourfathi H, Eagan A, et\u00a0al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022;163(2):e293\u2013309.","journal-title":"Pain"},{"issue":"1","key":"410_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137.","journal-title":"J Headache Pain."},{"issue":"9","key":"410_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629\u2013808.","journal-title":"Cephalalgia"},{"issue":"1","key":"410_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1\u201318.","journal-title":"Headache"},{"issue":"10","key":"410_CR5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1177\/0333102415620251","volume":"36","author":"K Laurell","year":"2016","unstructured":"Laurell K, Artto V, Bendtsen L, et\u00a0al. Premonitory symptoms in migraine: a cross-sectional study in 2714 persons. Cephalalgia. 2016;36(10):951\u20139.","journal-title":"Cephalalgia"},{"issue":"4","key":"410_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S1474-4422(20)30482-8","volume":"20","author":"KG Vetvik","year":"2021","unstructured":"Vetvik KG, MacGregor EA. Menstrual migraine: a distinct disorder needing greater recognition. Lancet Neurol. 2021;20(4):304\u201315.","journal-title":"Lancet Neurol"},{"key":"410_CR7","unstructured":"EMGALITY\u00ae (galcanezumab) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019."},{"issue":"10","key":"410_CR8","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1177\/0333102419840780","volume":"39","author":"W Kielbasa","year":"2019","unstructured":"Kielbasa W, Helton DL. A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39(10):1284\u201397.","journal-title":"Cephalalgia"},{"issue":"8","key":"410_CR9","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442\u201354.","journal-title":"Cephalalgia"},{"issue":"9","key":"410_CR10","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080\u20138.","journal-title":"JAMA Neurol"},{"issue":"24","key":"410_CR11","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211\u201321.","journal-title":"Neurology"},{"key":"410_CR12","unstructured":"EMGALITY\u00ae (galcanezumab) [package insert]. Kobe, Japan: Eli Lilly Japan K.K.; 2021."},{"issue":"1","key":"410_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17(1):15\u201322.","journal-title":"Cephalalgia"},{"issue":"1","key":"410_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1526-4610.2004.04004.x","volume":"44","author":"T Takeshima","year":"2004","unstructured":"Takeshima T, Ishizaki K, Fukuhara Y, et\u00a0al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache. 2004;44(1):8\u201319.","journal-title":"Headache"},{"key":"410_CR15","first-page":"1","volume":"3","author":"F Sakai","year":"2020","unstructured":"Sakai F, Ozeki A, Skljarevski V. Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: a phase 2 randomized controlled clinical trial. Cephalalgia Rep. 2020;3:1\u201310.","journal-title":"Cephalalgia Rep"},{"issue":"1","key":"410_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-021-01215-9","volume":"22","author":"M Ament","year":"2021","unstructured":"Ament M, Day K, Stauffer VL, et\u00a0al. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine. J Headache Pain. 2021;22(1):6.","journal-title":"J Headache Pain"},{"issue":"1","key":"410_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s10194-020-01190-7","volume":"21","author":"J Ailani","year":"2020","unstructured":"Ailani J, Andrews JS, Rettiganti M, Nicholson RA. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials). J Headache Pain. 2020;21(1):123.","journal-title":"J Headache Pain"},{"issue":"3","key":"410_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/head.13446","volume":"59","author":"SD Silberstein","year":"2019","unstructured":"Silberstein SD, Rapoport AM, Loupe PS, et\u00a0al. The effect of beginning treatment with fremanezumab on headache and associated symptoms in the randomized phase 2 study of high frequency episodic migraine: post-hoc analyses on the first 3 weeks of treatment. Headache. 2019;59(3):383\u201393.","journal-title":"Headache"},{"issue":"14","key":"410_CR19","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1177\/03331024211028966","volume":"41","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Dodick DW, Kudrow D, et\u00a0al. Reduction in migraine pain intensity in patients treated with erenumab: a post hoc analysis of two pivotal randomized studies. Cephalalgia. 2021;41(14):1458\u201366.","journal-title":"Cephalalgia"},{"issue":"3","key":"410_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1046\/j.1526-4610.2003.03050.x","volume":"43","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Lipton RB, Kolodner K. Migraine disability assessment (MIDAS) score: relation to headache frequency, pain intensity, and headache symptoms. Headache. 2003;43(3):258\u201365.","journal-title":"Headache"},{"key":"410_CR21","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.2147\/JPR.S287781","volume":"13","author":"M Shibata","year":"2020","unstructured":"Shibata M, Nakamura T, Ozeki A, Ueda K, Nichols RM. Migraine-Specific Quality-of-Life Questionnaire (MSQ) version 2.1 score improvement in Japanese patients with episodic migraine by galcanezumab treatment: Japan Phase 2 study. J Pain Res. 2020;13:3531\u20138.","journal-title":"J Pain Res"},{"issue":"1","key":"410_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40120-021-00236-5","volume":"10","author":"Y Tatsuoka","year":"2021","unstructured":"Tatsuoka Y, Takeshima T, Ozeki A, Matsumura T. Treatment satisfaction of galcanezumab in Japanese patients with episodic migraine: a Phase 2 randomized controlled study. Neurol Ther. 2021;10(1):265\u201378.","journal-title":"Neurol Ther"},{"issue":"7","key":"410_CR23","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/head.13330","volume":"58","author":"LL Hanson","year":"2018","unstructured":"Hanson LL, Ahmed Z, Katz BJ, et\u00a0al. Patients with migraine have substantial reductions in measures of visual quality of life. Headache. 2018;58(7):1007\u201313.","journal-title":"Headache"},{"issue":"1","key":"410_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1526-4610.2012.02292.x","volume":"53","author":"RB Lipton","year":"2013","unstructured":"Lipton RB, Buse DC, Saiers J, Fanning KM, Serrano D, Reed ML. Frequency and burden of headache-related nausea: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013;53(1):93\u2013103.","journal-title":"Headache"},{"issue":"1","key":"410_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/head.12450","volume":"55","author":"ML Reed","year":"2015","unstructured":"Reed ML, Fanning KM, Serrano D, Buse DC, Lipton RB. Persistent frequent nausea is associated with progression to chronic migraine: AMPP study results. Headache. 2015;55(1):76\u201387.","journal-title":"Headache"},{"issue":"1","key":"410_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-020-01180-9","volume":"21","author":"S Kikui","year":"2020","unstructured":"Kikui S, Chen Y, Todaka H, Asao K, Adachi K, Takeshima T. Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey. J Headache Pain. 2020;21(1):110.","journal-title":"J Headache Pain"},{"issue":"5","key":"410_CR27","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3390\/jcm11051228","volume":"11","author":"M Albanese","year":"2022","unstructured":"Albanese M, Mercuri NB. Could the new anti-CGRP monoclonal antibodies be effective in migraine aura? Case reports and literature review. J Clin Med. 2022;11(5):1228.","journal-title":"J Clin Med"},{"issue":"6","key":"410_CR28","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1007\/s00415-021-10546-1","volume":"268","author":"E Matteo","year":"2021","unstructured":"Matteo E, Pensato U, Favoni V, Giannini G, Pierangeli G, Cevoli S. Do anti-CGRP drugs have a role in migraine aura therapy? J Neurol. 2021;268(6):2273\u20134.","journal-title":"J Neurol"},{"issue":"1","key":"410_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-021-01344-1","volume":"22","author":"A Straube","year":"2021","unstructured":"Straube A, Stude P, Gaul C, Schuh K, Koch M. Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany. J Headache Pain. 2021;22(1):133.","journal-title":"J Headache Pain"},{"issue":"2","key":"410_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/jamaneurol.2021.4678","volume":"79","author":"M Ashina","year":"2022","unstructured":"Ashina M, Goadsby PJ, Dodick DW, et\u00a0al. Assessment of erenumab safety and efficacy in patients with migraine with and without aura: a secondary analysis of randomized clinical trials. JAMA Neurol. 2022;79(2):159\u201368.","journal-title":"JAMA Neurol"},{"issue":"7","key":"410_CR31","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s00415-020-09726-2","volume":"268","author":"LM Cupini","year":"2021","unstructured":"Cupini LM, Corbelli I, Sarchelli P. Menstrual migraine: what it is and does it matter? J Neurol. 2021;268(7):2355\u201363.","journal-title":"J Neurol"},{"issue":"9","key":"410_CR32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/j.1468-2982.2004.00741.x","volume":"24","author":"F Granella","year":"2004","unstructured":"Granella F, Sances G, Allais G, et\u00a0al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004;24(9):707\u201316.","journal-title":"Cephalalgia"},{"issue":"4","key":"410_CR33","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1526-4610.2010.01625.x","volume":"50","author":"EA MacGregor","year":"2010","unstructured":"MacGregor EA, Victor TW, Hu X, et\u00a0al. Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial. Headache. 2010;50(4):528\u201338.","journal-title":"Headache"},{"issue":"1","key":"410_CR34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s10194-020-01167-6","volume":"21","author":"JM Pavlovic","year":"2020","unstructured":"Pavlovic JM, Paemeleire K, G\u00f6bel H, et\u00a0al. Efficacy and safety of erenumab in women with a history of menstrual migraine. J Headache Pain. 2020;21(1):95.","journal-title":"J Headache Pain"},{"issue":"2","key":"410_CR35","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s40122-021-00273-w","volume":"10","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, Orologio I, Bonavita S, et\u00a0al. Effectiveness and safety of CGRP-mAbs in menstrual-related migraine: a real-world experience. Pain Ther. 2021;10(2):1203\u201314.","journal-title":"Pain Ther"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00410-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00410-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00410-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T08:58:08Z","timestamp":1701248288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00410-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["410"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00410-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"assertion":[{"value":"5 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}